About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, November 3rd, 2017

The QualityStocks
Daily Stock List


Kalytera Therapeutics, Inc. (KALTF)

OTC Markets, InvestorsHub, Stockhouse, Stockwatch, The Street, Dividend Investor, and Investing reported on Kalytera Therapeutics, Inc. (KALTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A clinical-stage pharmaceutical company, Kalytera Therapeutics, Inc. is pioneering the development of a next generation of cannabinoid therapeutics. The Company is working to establish a leading position in the development of novel cannabinoid medicines for a spectrum of important unmet medical needs, with an initial emphasis on Graft versus Host Disease (GvHD). Listed on the OTCQB, Kalytera Therapeutics has its U.S. headquarters in Novato, California and its research facility in Israel.

GvHD is a multisystem disorder. It is a common, life-threatening complication of hematopoietic stem cell transplant (HCT) procedures. GvHD occurs when the transplanted donor cells attack the patient’s organs. This includes the skin, gastrointestinal tract, liver, lungs, and eyes.

The Company is also developing a new class of proprietary cannabidiol (CBD) therapeutics. Its intention is to file composition of matter and method of use patents covering its novel inventions.

Kalytera Therapeutics’ intention is to explore the use of CBD, a non-psychoactive cannabis constituent. It is working to advance a portfolio of synthetic, non-psychoactive cannabis-like molecules. In addition, Kalytera will center on orphan conditions, with the objective of generating data in humans, which may support follow-on studies in major conditions.

Regarding Kalytera Therapeutics’ Graft versus Host Disease (GvHD) Program, four Phase 2a clinical trials are complete, as well as one published study demonstrating proof-of-concept. Orphan Drug Designation (ODD) has been granted in the United States and Europe. In addition, the Company is advancing towards Phase 2b randomized, placebo-controlled clinical studies.

Recently, Kalytera Therapeutics announced that it received approval from the Institutional Review Board (IRB) at one of two clinical sites in Israel. This is to begin a Phase 2 study to evaluate cannabidiol (CBD) for the prevention of GvHD.

The proposed study is a Phase 2, open label, multicenter trial. This trial is to evaluate the pharmacokinetic profile, safety, and efficacy of multiple doses of CBD for the prevention of GvHD following allogeneic hematopoietic cell transplantation (HCT). This proposed study will take place at the Rabin Medical Center, Beilinson, and the Rambam Health Care Campus, Haifa, in Israel.

Last month, Kalytera Therapeutics announced that Mr. Robert Farrell, J.D., was appointed as the Company's Chief Executive Officer (CEO). Mr. Farrell previously held the position of Interim CEO.

He has greater than 25 years of experience in the pharmaceutical, biotechnology, and medical device sectors. Before joining Kalytera Therapeutics, Mr. Farrell worked as an Executive Officer with the Institute for One World Health, which is an affiliate of the Bill and Melinda Gates Foundation.

Kalytera Therapeutics, Inc. (KALTF), closed Friday's trading session at $0.0686, down 0.58%, on 103,450 volume with 5 trades. The average volume for the last 60 days is 43,383 and the stock's 52-week low/high is $0.061/$0.799.

Frontier Oilfield Services, Inc. (FOSI)

Stockopedia, MarketWatch, Marketwired, and InvestorsHub reported on Frontier Oilfield Services, Inc. (FOSI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Frontier Oilfield Services, Inc. specializes in saltwater recovery and drilling fluid disposal. The Company has growing operations centered in East Texas' Haynesville Shale and North Texas' Barnett Shale. Frontier serves national, integrated, as well as independent oil and gas exploration companies.

Frontier Oilfield Services lists on the OTC Markets Group’s OTCQB. The Company formerly went by the name TBX Resources, Inc. It changed its corporate name to Frontier Oilfield Services, Inc. in February of 2012.

In 2010, Frontier Oilfield Services’ operations commenced with seven permitted disposal wells in Harrison and Panola Counties. These are situated in Texas along the Louisiana state line. In July of 2011, the Company acquired an eighth disposal well. This well expanded Frontier’s capacity in its main area of operations.

Frontier’s oilfield services include hydraulic fracturing fluid recovery and disposal, and saltwater disposal well schematic. The Company assists enterprises in meeting their saltwater disposal needs.

Hydraulic-fracturing (fracking) has changed the panorama of oil and gas in the United States. Advances in technology have set the stage for extracting huge deposits of oil and gas buried deep beneath the surface. This push for development has led to significant opportunities for oilfield services companies specializing in assisting operators in managing critical drilling fluid and saltwater disposal (SWD).

Frontier has an established record of accomplishment providing logistically sound, compliant, safe, and environmentally sound saltwater disposal to some of the Haynesville Shale's and the Barnett Shale's largest operators.

In July of 2012, Frontier Oilfield Services purchased Chico Coffman Tank Trucks, Inc. Coffman Tank Trucks is one of the largest saltwater disposal companies serving North Central Texas’ Barnett Shale. It operates trucks twenty-four hours a day, seven days a week.

Frontier Oilfield Services’ East Texas operations company, Trinity Disposal and Trucking and its North Central Texas operations company, Coffman Tank Trucks, has a first-rate roster of clients. These clients include Devon Energy, GMX Resources, Wagner & Brown, Ltd., Matador Oil, NFR Energy, Vernon Faulkner, and XTO Energy.

Frontier Oilfield Services, Inc. (FOSI), closed Friday's trading session at $0.45, down 30.23%, on 2,052 volume with 3 trades. The average volume for the last 60 days is 4,009 and the stock's 52-week low/high is $0.13/$4.00.

Cannabics Pharmaceuticals, Inc. (CNBX)

Wealth Insider Alert, Wall Street Mover, SmallCapVoice, StreetAuthority Daily, Wall Street Daily, TopPennyStockMovers, Stockgoodies, Promotion Stock Secrets, Cannabis Financial Network News, Market Intelligence Center, and TheMicrocapNews reported earlier on Cannabics Pharmaceuticals, Inc. (CNBX), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Cannabics Pharmaceuticals, Inc.’s dedication is to the development of advanced cannabinoid-based treatments and therapies. The Company’s principal focus is the development of novel therapies and biotechnological tools designed to provide relief from varied ailments and treat human malignancies. Cannabics’ vision is to create individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools. Cannabics Pharmaceuticals is based in Bethesda, Maryland.

The Company has licensed Research and Development (R&D) based in Israel. This R&D’s devotion is to the development of palliative and personalized anti-cancer treatments channelling the multipurpose therapeutic values of cannabinoids to create tailored therapies for cancer patients. Cannabics’ integrated technology has created a successful medically standardized delivery system providing patients natural, reliable, and also safe therapy.

Cannabics Pharmaceuticals’ advanced tools include novel delivery systems, personalized medicine diagnostics, and therapies based on cannabinoid compounds. Its primary technology is Cannabics SR. This technology is for a long acting oil capsule that provides a safe, effective, and reliable administration of cannabis. The technology’s composition is exclusively from food grade materials.

Cannabics Pharmaceuticals announced this past July that it executed a Collaboration Agreement with SIMFO GmbH. Under this Agreement, Cannabics shall be the exclusive global provider of SIMFO's CTC diagnostics to cancer patients treated with natural cannabinoids.

The diagnostics include a count of circulating tumor cells (CTC) and drug sensitivity tests of different cannabinoids, for example THC, THCA, CBD, and CBDA. SIMFO (located in Germany) is a worldwide leader in cancer diagnostics and liquid biopsies.

Cannabics Pharmaceuticals has established a Genetic lab that will develop diagnostic tools based on human genome, tumor genetics, and cannabinoids. The Company recruited Dr. Moran Grinberg to serve as its VP of R&D and to lead the Genetic research. Dr. Grinberg has a PhD in Virology and MSc in clinical pharmacology with wide-ranging experience in conceptualizing and executing pharmacological research.

Recently, Cannabics Pharmaceuticals announced that it filed an extensive provisional patent application with the US Patent & Trademark Office (USPTO). This is on a new Method for Sensitivity Tests of Cannabinoids on Patient-Derived Tumor Biopsies and CTCs. The method, developed by Cannabics Pharmaceuticals, expands its proprietary technology of personalization of cannabinoid medicine.

Furthermore, Cannabics has filed national phase patent applications for its 'System and Method for High Throughput Screening of Cancer Cells.' These were filed in the U.S., Canada, Europe, China, India, Brazil, and Australia.

Cannabics Pharmaceuticals, Inc. (CNBX), closed Friday's trading session at $0.81, up 10.66%, on 407,481 volume with 226 trades. The average volume for the last 60 days is 207,511 and the stock's 52-week low/high is $0.353/$7.60.

Southern Silver Exploration Corp. (SSVFF)

Real Pennies and Streetwise Reports reported previously on Southern Silver Exploration Corp. (SSVFF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Southern Silver Exploration Corp. is a precious metals exploration and development enterprise. The Company centers on the discovery of world-class mineral deposits in north-central Mexico and the southern United States. Its growth strategy is to concentrate on the development of quality assets, in significant mineralized trends, close to infrastructure. Southern Silver Exploration has its corporate office in Vancouver, British Columbia.

Southern Silver involves in the acquisition, exploration, and development, either directly or via joint-venture (JV) relationships, in mineral properties in major jurisdictions. The Company’s specific focus is the Cerro Las Minitas silver-lead-zinc project positioned in the heart of Mexico's Faja de Plata.

Southern Silver Exploration is focusing on its exploration efforts in developing the Cerro Las Minitas project into a premier, high-grade, silver-lead-zinc mine. The Cerro Las Minitas silver-lead-zinc property is greater than 130 square kilometers in size. The Cerro Las Minitas property consists of 18 concessions, totaling roughly 13,640 hectares.

The Company’s property portfolio also includes its 100 percent owned Oro porphyry copper-gold project in southern New Mexico. This is a 1,150 hectare, gold, silver, copper, lead and zinc property. Oro features a classic porphyry zonation over a six-square kilometer area within the highly prospective Laramide Porphyry belt of the southern United States. The Oro Project consists of eight patented mining claims and 89 BLM (Bureau of Land Management) mineral claims.

In May 2017, Southern Silver Exploration announced that it acquired strategic mineral claims adjacent to the southwest of its Cerro Las Minitas project. The claim package consists of two concessions, known as Biznagas and Los Lenchos, totaling 9600 hectares. These are contiguous to the south and west with the Cerro Las Minitas claim block.

Recently, Southern Silver Exploration reported that it intersected the down-dip projection of two mineralized zones in the newly identified Las Victorias target situated southeast of the known mineral deposits on the Cerro Las Minitas project. The mineral intercepts from drill hole 17CLM-105 are significant since: they confirm the extension of the Blind Zone and Skarn Front deposits to the southeast of their earlier drilled extents. Furthermore, they open a 500 meter strike-length of new target area for more drill testing.

Last month, Southern Silver Exploration reported that Phase II drilling on the Stockpond gold target has started on the Company’s Oro project. The program will comprise 8-10 reverse-circulation (RC) drill holes totaling about 1,200m that will test lateral offsets of gold mineralization identified in 2016 drilling. Moreover, results of a +300-line kilometer airborne Z-TEM survey over the entire Oro property have been received and evaluated. This has resulted in more claims being staked to cover new targets, which now have been sampled for further evaluation.

Southern Silver Exploration Corp. (SSVFF), closed Friday's trading session at $0.2246, down 2.94%, on 2,000 volume with 1 trade. The average volume for the last 60 days is 34,118 and the stock's 52-week low/high is $0.1933/$0.456.

Sunset Island Group, Inc. (SIGO)

PennyStockSpy, OTCPicks, MicrocapVoice, and 007 Stock Chat reported previously on Sunset Island Group, Inc. (SIGO), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Sunset Island Group, Inc. provides consulting and advisory services to clients operating in the medical marijuana business arena. The Company centers on providing a licensed manufacturing facility to clients for producing products, such as oils and edibles. Sunset Island Group lists on the OTC Markets Group’s OTCQB. The Company is based in San Clemente, California.

Fundamentally, Sunset Island Group’s vision is to establish a fully integrated company that provides turnkey solutions to the medical cannabis industry. Its principal focus is on providing a licensed facility where companies can manufacture and produce their products. Also, it will provide distribution for companies by way of an established network of dispensaries.

Sunset Island Group earlier secured a lease on a property approved for cannabis cultivation. The Company’s space underwent inspection in April of this year as part of the permitting process. Sunset Island filed for permits for 22,000 square feet of green house space. The expectation is that the 22,000 square feet of green house space will be able to produce up to 4,000 pounds of medical cannabis annually.

Sunset Island announced in February 2017 that it began development of a CBD dietary supplement product. The initial product will feature a 2-oz stress relief beverage made from highest quality legal Hemp/CBD oil and real fruit.

These products will at first sell via the Company’s website. Sunset Island expects to expand by selling through Amazon and other retailers. It will continue to develop products that will address the demands in the international dietary supplements market, targeted to soon reach in excess of $200 billion.

The product will be developed by a trained French Chef with over 20 years of experience in Product Development and Food Production. In addition, this Chef has developed products from their concept stage to national distribution that have produced more than $100 million in sales.

According to industry research firm GreenWave Advisors, the consumption of marijuana for medical and recreational use could increase to a $35 billion market by the year 2020. GreenWave Advisors tracks retail sales in the four states and the District of Columbia (DC), which have already legalized it.

In late September, Sunset Island Group announced that it started a retrofit to its present grow space, which will substantially increase the amount of cannabis product produced with each harvest.

T.J. Magallanes, Chief Executive Officer, stated, "The obvious solution to increasing the number of pounds of cannabis produced each year is more space, but effective utilization of the space that you already have is also important. With that in mind, effective immediately we are retrofitting our original 10,000 square feet of grow space at a cost of approximately $75,000. The return on this investment will be considerable and we predict we will be able to increase our yield by 50 percent.”

Moreover, the Company announced this month that it has started an aggressive expansion of its cannabis product line.

Sunset Island Group, Inc. (SIGO), closed Friday's trading session at $0.5599, up 3.69%, on 20,954 volume with 19 trades. The average volume for the last 60 days is 176,392 and the stock's 52-week low/high is $0.0647/$10.00.

Innovative Food Holdings, Inc. (IVFH)

Marketbeat, Stock Guru, The Bowser Report, and FeedBlitz reported previously on Innovative Food Holdings, Inc. (IVFH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Innovative Food Holdings, Inc. is an industry leading specialty food platform. The Company, by way of its subsidiaries, is a top nationwide provider of direct from source specialty foods, healthcare foods, gluten free foods, and artisanal foods, to the professional foodservice market. Perishable product is delivered direct to the Company’s kitchen the next day via overnight delivery. Non-perishable product is delivered direct to customers. The Company’s wholly-owned subsidiary is Artisan Specialty Foods. Innovative Food Holdings is based in Bonita Springs, Florida.

Artisan Specialty Foods is a nationwide specialty food distributer, re-packer, as well as importer. Artisan serves hundreds of customers in the Chicago area. In addition, it serves as a nationwide fulfillment center for other Innovative Food Holdings subsidiaries operating in the foodservice and direct-to-consumer markets.

In the direct-to-chef foodservice market, Innovative Food Holdings’ automated direct-to-chef platform provides efficient, cost effective, and transparent direct sourcing and distribution of more than 7,000 specialty food products delivered each day, to thousands of chefs across the nation.

Available products include origin specific seafood, exotic meats and game, dry-aged meats, exotic fruits and vegetables, specialty chocolates, artisanal cheeses, and imported specialties. Furthermore, available products include caviar, wild and cultivated mushrooms, micro-greens, heirloom and baby produce, organic farmed and manufactured food products, estate-bottled olive oils, aged vinegars, and healthcare food products.

Innovative Food Holdings serves restaurants, hotels, country clubs, national chain accounts, casinos, and catering houses. Many of its products are used each day by a host of some of the foremost professional chefs throughout the U.S.

The Company supplies chefs with innovative, organic, sustainable, and artisanal products sourced from all areas around the world. The Company markets its products directly to the consumer, through its website at www.forthegourmet.com.

This past August, Innovative Food Holdings reported financial results for Q2 ended June 30, 2017. Revenue grew more than 26 percent to $10.5 million versus $8.3 million for Q2 of 2016. GAAP Fully Diluted EPS rose by more than 100 percent to $0.04 versus $0.02 per share for Q2 of 2016.

Revenue increased more than 22 percent to about $20 million versus $16.3 million for the six months of 2016. GAAP Fully Diluted EPS increased by 100 percent to $0.07 versus $0.035 per share for the first six months of 2016.

Innovative Food Holdings, Inc. (IVFH), closed Friday's trading session at $0.989, up 2.86%, on 94,441 volume with 33 trades. The average volume for the last 60 days is 129,204 and the stock's 52-week low/high is $0.395/$1.08.

IBC Advanced Alloys Corp. (IAALF)

Pro-Edge, Cool Penny Stocks, PennyInvest, PennyStockVille, Equities, equities Canada, The Howard Group, InvestorIntel, and BullRally reported on IBC Advanced Alloys Corp. (IAALF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

IBC Advanced Alloys Corp. is a top beryllium and copper advanced alloys company. IBC serves a variety of industries including defense, aerospace, automotive, telecommunications, precision manufacturing, and others. The Company has its Copper Division and its Engineered Materials Division. IBC Advanced Alloys is headquartered in Franklin, Indiana. It has production facilities in Indiana, Massachusetts, Pennsylvania, and Missouri. The Company’s shares trade on the OTCQB.

IBC Advanced Alloys’ Copper Division manufactures and distributes an array of copper alloys as castings and forgings. These include beryllium copper, chrome copper, as well as aluminum bronze. The Company’s Engineered Materials Division makes the Beralcast® family of alloys. These can be precision cast. They are utilized in an increasing number of defense, aerospace, and other systems. This includes the F-35 Joint Strike Fighter.

In May of this year, IBC Advanced Alloys announced that it was awarded a production contract from Raytheon Space and Airborne Systems (RTN). This contract is to produce a beryllium-aluminum cast component for use in Raytheon's Advanced Targeting Forward Looking Infrared (ATFLIR) system, which is now in use on U.S. Navy F/A-18 fighter jets.

The part is a precision cast pitch gimbal housing for the ATFLIR system. It is produced from IBC's proprietary Beralcast® beryllium-aluminum material.

IBC Advanced Alloys has completed the major components of its capital improvements program, which it launched in 2016. This includes installation and operational status of advanced production furnaces in the Company’s copper alloys and beryllium alloys divisions.

This week, IBC Advanced Alloys announced its Fiscal Q4 2017 and full-year 2017 financial results. Revenue for the quarter ended June 30, 2017 was $4.2 million. This represents a 2.4 percent increase over Revenues of $4.1 million in the quarter ended June 30, 2016. The Company reported a loss in the quarter of $2.2 million, or ($0.07) per basic and diluted share, versus a loss of $1.1 million in the quarter ended June 30, 2016, or ($0.06) per basic and diluted share.

Year-end Revenue for fiscal 2017 was reported at $15.7 million, a drop from fiscal 2016 Revenue of $16.4 million. IBC Advanced Alloys reported a fiscal 2017 loss of $5.4 million. This represents a loss per share of $0.18, versus a fiscal year 2016 loss of $3.9 million, representing a loss per share of $0.33.

IBC Advanced Alloys Corp. (IAALF), closed Friday's trading session at $0.1853, up 0.60%, on 11,541 volume with 3 trades. The average volume for the last 60 days is 19,592 and the stock's 52-week low/high is $0.1842/$0.404.


The QualityStocks
Company Corner


AV1 Group, Inc. (AVOP)

The QualityStocks Daily Newsletter would like to spotlight AV1 Group, Inc. (AVOP). Today, AV1 Group, Inc. closed trading at $0.0427, up 20.28%, on 20,954 volume with 19 trades. The stock’s average daily volume over the past 60 days is 176,392 and its 52-week low/high is $0.0647/$10.00.

AV1 Group, Inc. (AVOP), is a publicly traded investment and holding company established to identify, secure and monetize emerging growth companies in a number of sectors that include cannabis related technologies, grow houses and cultivation, and e-commerce businesses positioned for exponential growth. After identifying businesses displaying revolutionary concepts able to develop a substantial footprint in high-growth markets, the business model followed calls for incubating and supporting the best opportunities.

The company seeks to discover inspired entrepreneurs with innovative ideas that are poised for significant revenue generation. Management expertise can be seen in the development of embryonic-stage subsidiaries as the company brings a spectrum of backgrounds to the table with a significant resource of knowledge and experience to every venture. AV1 Group explores every opportunity to help each sector exceed its revenue goals while building close, active working relationships as it prepares each respective division to be a robust competitor within the various chosen markets.

AV1 Group companies include:

  • XFIRESmartSystems.com – Intelligent lighting solutions and wireless access for many different applications.
  • VaporHighUSA.com – Over 800 vaping products; bitcoin payments accepted.
  • DentalCannatizer.com – Revolutionary dual jet dental water jet integrates hemp oil infusing.
  • IntelligentLightingCorp.com – Comprehensive, energy-efficient lighting solutions.
  • CannaLighting.com – Wholly owned subsidiary building strategic relationships in the LED sector to provide solutions for grow houses and cultivation centers.
  • MJIQ – First, comprehensive, enterprise-grade integrated software suite being developed for the legal cannabis industry.
  • Hemptory.com – Engaging online destination for all hemp and cannabis related products and services.
  • Lawster.com – Puts consumers and small businesses in contact with legal services and service providers.
  • MJTestLabs.com – Under development website will serve cannabis dispensaries, laboratories and industry affiliates.

AV1 Group's business model delivers an advantage with internally-created projects that are poised for revenue generation and a cross-company revenue platform that enables the company to incubate and foster growth in early-stage subsidiaries under one umbrella. Disclaimer

AV1 Group, Inc. Blog

AV1 Group, Inc. News:

AV1 Group, Inc. (AVOP) is “One to Watch”

AV1 Group Appoints New CFO and Digital Marketing Director

AV1 Group Enters Key Strategic Relationship with Experienced Privately Held LED Lighting Company with International Footprint

Zinc One Resources, Inc. (TSX-V: Z) (OTC: ZZZOF) (FSE: RH33)

The QualityStocks Daily Newsletter would like to spotlight Zinc One Resources, Inc. (ZZZOF). Today, Zinc One Resources, Inc. closed trading at $0.353, off by 0.81%, on 130,673 volume with 30 trades. The stock’s average daily volume over the past 60 days is 53,093 and its 52-week low/high is $0.011/$0.81.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Zinc One Resources, Inc. (TSXV: Z) (OTC Pink: ZZZOF) (FSE: RH33), a client of NNW focused on the acquisition, exploration and development of prospective and advanced zinc projects in mining-friendly jurisdictions. The publication, titled, "Zinc Producers in Spotlight as Demand Powers Past Supply," discusses how the persistent demand for zinc as the supply runs low has created opportunities for some smaller zinc producers. To view the full publication, visit: https://www.networknewswire.com/zinc-producers-spotlight-demand-powers-past-supply/

Zinc One Resources, Inc. (TSX-V: Z) (OTC: ZZZOF) (FSE: RH33) is a Vancouver, Canada-based company focused on the acquisition, exploration and development of prospective and advanced zinc projects in mining friendly jurisdictions. Zinc One's key assets are the Bongará Zinc Mine and Charlotte-Bongará Zinc-Oxide Project in north-central Peru. Historical production of the Bongará Mine, which was mined from 2007-2008 until a fall in zinc prices shut it down, revealed greater than 20 percent zinc grades and recoveries over 90 percent, all from surface mining. Bongará's high grade zinc mineralization is considered a rare situation and one that Zinc One management is poised to explore further. The neighboring Charlotte-Bongará Zinc-Oxide Project has multiple at-surface, high-grade drill intercepts providing numerous drill targets.

Zinc One controls both zinc-oxide mine projects, making it the first time a single operator has been in control of the two locations, giving the company a unique opportunity to delineate a substantial high-grade, zinc-oxide resource along a 4 kilometres-long trend. A previous operator produced 55.1 million pounds of zinc, running at 358 tonnes a day. Zinc One has access to all data and technical work dating back to the 1990s and controls a third zinc prospect located in central Peru as part of its portfolio.

The company has also received approval from Peru's Ministry of Energy and Mines to suspend the mine closure at the Bongará location, which allows Zinc One to utilize the current Environmental Impact Assessment attached to the project for current and future permitting. This critical approval allows the company to take another important step forward in its plans to reopen production at the Bongará zinc-oxide project. Zinc One's project locations involve open pit/surface mining, requiring less infrastructure and a much better cost ratio than traditional underground mines.

Zinc One is managed by a proven team of exploration geologists and engineers with extensive experience in constructing and operating successful mining operations. The company's business strategy includes restarting production at the Bongará Zinc-Oxide Mine with exploration of targets along a 6-kilometer strike as well as exploring the Charlotte Bongará Zinc-Oxide Project.

World stockpiles of zinc are at multiyear lows while demand continues to be strong. In 2016, zinc demand became greater than the available supply for the first time in a decade. Zinc is essential for rustproofing steel and is used in a variety of infrastructures. It's also used to produce batteries, fertilizers, paints, plastics, cosmetics and multivitamins. The International Zinc Association estimates that zinc could save the world over $300 billion annually in direct corrosion costs and another $300 billion annually in indirect costs. Zinc is an invaluable base metal and a strategic priority for many industries. Disclaimer

Zinc One Resources, Inc. Blog

Zinc One Resources, Inc. News:

NetworkNewsWire Announces Publication Highlighting Zinc Producers Competing to Meet Rising Demand

NetworkNewsWire Announces Publication Discussing the Future of Zinc, Forecasted for Steady Growth

Zinc One Reports High-Grade Zinc Results From Surface Samples at Bongara Zinc Mine Project

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.599, up 14.10%, on 661,789 volume with 306 trades. The stock’s average daily volume over the past 60 days is 118,848 and its 52-week low/high is $0.1701/$0.699.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a client of NNW that develops and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. The publication, entitled, "Bioabsorption Breakthrough Shows Promise for Tobacco, Cannabinoids, Medication," highlights a patented delivery method created by Lexaria Bioscience, and its application to cannabinoids, fat soluble vitamins, non-steroidal anti-inflammatory pain medications ("NSAIDs"), and even nicotine. To view the full publication, visit: https://www.networknewswire.com/bioabsorption-breakthrough-shows-promise-tobacco-cannabinoids-medication/

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsWire Announces Publication on the Wide-Ranging Potential of Patented Technology for Improved Bioabsorption

Lexaria Bioscience Receives Groundbreaking U.S. Patent Allowance for its DehydraTECH™ Delivery of THC, NSAIDs, Nicotine and Vitamins

NetworkNewsWire Announces Publication Highlighting Recent Developments in Drug Delivery Technologies

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.4599, up 4.52%, on 31,133 volume with 9 trades. The stock’s average daily volume over the past 60 days is 43,315 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (OTC: ORHB), an advanced digital software company focused on real-time data analytics, today announces that all series of its outstanding warrants, scheduled to expire on December 31, 2017, will expire in accordance with their terms on such date and will not be further extended. ORHub currently has approximately 30 million warrants outstanding in five series. As previously announced on June 21, 2017, the Series B and Series D warrants are exercisable at $0.50. The Series C, E, and F Warrants are exercisable at $3.00, $4.00 and $4.00 respectively.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. (ORHB) Warrants Set to Expire on December 31, 2017

ORHub, Inc. Announces Additional Deployment of Disruptive Surgical Information Software at Three Leading Hospitals in Southern California

ORHub, Inc. Appoints Industry-Leading Neurosurgeon and Orthopedic Surgeon to Advisory Board

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0186, up 3.33%, on 2,270,665 volume with 100 trades. The stock’s average daily volume over the past 60 days is 3,270,287, and its 52-week low/high is $0.0077/$0.04.

Global Payout, Inc. (OTCPink: GOHE) is pleased to announce that its majority owned subsidiary, MoneyTrac Technology, Inc. (“MTRAC”, the “Company”) has successfully sold the front cover of the premier of the Los Angeles addition of PotSaver, slated for release and mass distribution on January 1st, 2018.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

MoneyTrac Technology, Inc. Sells Front Cover of PotSaver’s Premier Los Angeles Edition

Global Payout’s MoneyTrac Technology, Inc. Co-Hosts Finance and Technology Networking Event for the Cannabis Industry

Global Payout's MoneyTrac Technology, Inc. Ramps-Up Sales and Marketing Efforts in Los Angeles County for PotSaver Brand

Medical Innovation Holdings, Inc. (MIHI)

The QualityStocks Daily Newsletter would like to spotlight Medical Innovation Holdings, Inc. (MIHI). Today, Medical Innovation Holdings, Inc. closed trading at $0.565, up 0.89%, on 117,501 volume with 51 trades. The stock’s average daily volume over the past 60 days is 45,308, and its 52-week low/high is $0.15/$3.99.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Medical Innovation Holdings, Inc. (OTC Pink: MIHI), a client of NNW that owns and operates strategically aligned healthcare service and product companies focused on the delivery of patient care, management services for physician offices, lab services, and pharma; and non-pharma medicines and alternatives to patients and consumers. The publication, titled, "The Promise of Telemedicine for American Health Care," discusses companies reducing the amount of underserved areas in health care services through the use of inventive telemedicine solutions. To view the full publication, visit: https://www.networknewswire.com/promise-telemedicine-american-health-care/

Medical Innovation Holdings, Inc. (MIHI), a Colorado-based publicly traded company, owns and operates strategically aligned healthcare service and product companies focused on the delivery of patient care, management services for physician offices, lab services, and pharma; and non-pharma medicines and alternatives to patients and consumers. Healthcare services are delivered and managed through the company's MSO, 3Point Care. 3Point Care uses virtual telemedicine with a unique customized software and hardware platform as a way of bringing quality medical care to rural and medically underserved areas (MUAs) of the country.

3Point Care provides personalized high-tech, high-touch telemedicine encounters that link virtual health specialty doctors with traditional primary physicians and their patients. This approach helps reduce the cost of care while enhancing the quality of care. The company's telemedicine approach is vastly different from other providers who rely on a monthly subscription to opt in the network and then require an encounter fee by the patient each and every time an on-demand physician is utilized. This approach breaks the continuum of care, relies on symptom-based diagnosis, does not accept insurance, and there is no certainty you are dealing with a licensed practitioner. In summation they are not a medical practice but a contract service to deliver virtual care. Because 3Point Care deploys doctors through an actual medical practice, there is no subscription fee. The company works with anyone and everyone that has insurance including Medicare and Medicaid. It works hand and hand with the patient's primary care physician so the continuum of care is always maintained. Part of the integrated software application enables the processing of insurance claims whereby doctors are paid for their services. This allows deductibles to be captured, allowing the patients to take advantage of medical tax deductions.

TeleLifeMd, a multi-disciplinary specialty healthcare practice with strong experience in telemedicine, is the primary deliverer of patient medical care. 3Point care has a unique and exclusive relationship with TeleLifeMD, acting as its management services organization by providing all levels of service that include scheduling, providing telemedicine hardware and software products and support, processing claims, paying all invoices and payroll incurred by TeleLifeMD, as well as any other service required to operate the practice.

BKare Diagnostics, another wholly owned subsidiary of MIHI, is tasked with delivering medical and health-related services such as laboratory testing, diagnostics, and alternative medicines primarily proven nutraceuticals. Its goal is to eventually infuse these products with 100% CBD/Hemp oil and THC-based oils to create new product categories as the law catches up with the cannabis marketplace. The opportunity to offer workable solutions that solve real health problems outside typical big pharma is very exciting for the company. It sees significant revenue opportunities in this space.

MIHI firmly believes the best way to provide access to high-quality medical care is through support and delivery of evidence-based virtual medicine, commonly known as telemedicine. With 80 million people living in rural, medically underserved areas of the nation, the company is poised to fill a glaring void in the healthcare industry by applying cutting-edge technology and time-tested business practices to deliver real-time care. Among the 16 areas of medical specialties available are cardiology, infertility, gastroenterology, pediatrics and obstetrics.

The company serves a number of constituents and stakeholders interested in reducing the cost of health care while simultaneously increasing the quality of care, improving access to health services for millions of people, and bringing value to company shareholders. Its unique platform incorporates every aspect of a telemedicine visit into a single, comprehensive package. Disclaimer

Medical Innovation Holdings, Inc. Company Blog

Medical Innovation Holdings, Inc. News:

NetworkNewsWire Announces Publication Highlighting Disruptive Business Models in Growing Telemedicine Sector

NetworkNewsWire Announces Publication Highlighting Revolutionary Solutions in the Telemedicine Market

Medical Innovation Holdings to be Featured on National Radio Telecasted Tuesday October 24th, 2017 at 10AM ET on Beasley Broadcasting

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA). Today, Marijuana Company of America Inc. closed trading at $0.0257, up 7.08%, on 11,005,857 volume with 361 trades. The stock’s average daily volume over the past 60 days is 4,367,739 and its 52-week low/high is $0.0181/$0.1985.

Marijuana Company of America Inc. (MCOA) (the "Company") are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA's CEO, founded the first marijuana company ever to trade on a US stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing expotentially and consequently the founders of MCOA have contructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can also be used to produce products that are carbon neutral or even carbon negative, like the longest, strongest natural fiber on earth, building materials that are mold, pest and fire proof, super foods and so much more for additional business opportunities. No part of the plant is left unused and the Company's overall stategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented exponential growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015's $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal and cannabis and industrial hemp sectors. The Company's business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA's strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product "hempSMART Brain," is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience. Disclaimer

Marijuana Company of America Inc. Blog

Marijuana Company of America Inc. News:

NetworkNewsBreaks – Marijuana Company of America (MCOA) Delivers Distinctive Cannabis Investment Opportunities

Marijuana Company of America (MCOA) Delivers with Unique Marketing, Distribution Platforms

Marijuana Company of America Engages NetworkNewsWire for Corporate Communications Solution


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(DCIX) +348.40%


(ILUS) +46.34%


(GOPH) +45.45%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251